MREO compared with TXMD: revenue, margins and what each company keeps, and the suppliers and customers both name

MREOMereo BioPharma Group plc

Mkt capRevenueRevenue

TXMDTherapeuticsMD, Inc.

Mkt capRevenueRevenue

Compare

MREOMereo BioPharma Group plc

TXMDTherapeuticsMD, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MREO

No earnings history for MREO.

TXMD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±18.3%▲+0.48%×0.03

= impliedMREO realized, solidTXMD realized, hatchedOne scale, both sides: full bar = 19%× = |realized| ÷ impliedSource: market data

MREOMereo BioPharma Group plc

0.28▲+0.46%· post 0.28

Mkt cap$45.2MRevenue$500,000Q2 FY25Revenue—

TXMDTherapeuticsMD, Inc.

1.66▼−2.92%· post 1.66

ClosedNov 6 '26

Mkt cap$20.3MRevenue$869,000Q2 FY26Revenue$3MFY25

Compare

ClosedNov 6 '26

MREOMereo BioPharma Group plc

TXMDTherapeuticsMD, Inc.

0.28▲+0.46%post 0.28

Price

1.66▼−2.92%post 1.66

$45.2M

Mkt cap

$20.3M

Q2 FY25$500,000

Revenue

$869,000Q2 FY26

—

Revenue

$3MFY25

MREO0.28▲+0.46%vsTXMD1.66▼−2.92%ClosedNov 6 '26